分析普米克令舒和博利康尼雾化吸入治疗小儿哮喘58例的临床疗效  

Analysis of clinical effect by pulmicort respulas and bricanyl aerosol inhalation in the treatment of 58 pediatric asthma cases

作　　者：李文华 

机构地区：[1]辽宁省海城市中心医院儿科,114200

出　　处：《中国现代药物应用》2016年第1期3-4,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨吸入用布地奈德混悬液(普米克令舒)和硫酸特布他林雾化液(博利康尼)雾化吸入治疗小儿哮喘的临床效果,总结提升小儿哮喘治疗质量的临床方法。方法 58例小儿哮喘患儿(实验组)给予普米克令舒和博利康尼雾化吸入治疗;同期58例小儿哮喘患儿(对照组)给予博利康尼雾化吸入治疗。对比两组临床疗效。结果实验组患儿总有效率、一秒用力呼气容积、呼气峰流速、氧分压等指标均优于对照组,差异具有统计学意义(P<0.05)。结论对于小儿哮喘患儿,选择普米克令舒和博利康尼雾化吸入治疗可以提升患儿治疗质量,临床可推广应用。Objective To investigate clinical effect by budesonide suspension for inhalation（pulmicort respulas） and terbutaline sulfate atomized liquid（bricanyl） aerosol inhalation in the treatment of pediatric asthma, and to summarize clinical method in improving treatment quality for pediatric asthma. Methods A total of 58 children with pediatric asthma（experimental group） received pulmicort respulas and bricanyl aerosol inhalation for treatment, and another 58 children with pediatric asthma in the same period（control group） received bricanyl aerosol inhalation for treatment. Their clinical effects were compared. Results The experimental group had better total effective rate, forced expiratory volume in one second, peak expiratory flow, and oxygen partial pressure than the control group. Their difference had statistical signficance（P〈0.05）. Conclusion Implement of pulmicort respulas and bricanyl aerosol inhalation in the treatment of pediatric asthma can improve treatment quality. It is worthy of clinical promotion and application.

关 键 词：吸入用布地奈德混悬液 硫酸特布他林雾化液 氧分压 小儿哮喘 

分 类 号：R725.6[医药卫生—儿科]